NASDAQ Framework: GoodRx Holdings Inc.

Digital healthcare platform offering prescription discounts 1.

GoodRx Holdings, Inc. is a consumer-focused digital healthcare platform that aims to lower the cost of healthcare in the United States. The company operates a price comparison platform that aggregates over 200 billion daily pricing data points to provide consumers with access to lower prices through discount codes and coupons for their medications. GoodRx generates revenue primarily from contracts with pharmacy benefit managers (PBMs) who pay commissions on prescription drug purchases made using GoodRx's discounts, as well as through subscription plans like GoodRx Gold and the Kroger Rx Savings Club. Founded in 2011 and headquartered in Santa Monica, California, GoodRx also offers other healthcare products and services, including telehealth services through the GoodRx Care platform 2 3 4.

2: Dropping Coverage of GoodRx GoodRx is a consumer-focused digital healthcare platform that aims to lower the cost of healthcare in the United States. It has over 6 million active monthly users. The company’s primary focus is the U.S. prescription drug market, where GoodRx has developed a price comparison tool that it aggregates from over 200 billion daily pricing data points, directing consumers toward coupons negotiated between a pharmacy and intermediaries (pharmacy benefit managers ). GoodRx generates revenue by taking a small share of the fees paid by pharmacies to PBMs in exchange for routing consumers to these discount programs, and separately through a subscription-based model (GoodRx Gold), which offers discounted drugs to customers paying a monthly membership fee. Morningstar• 2 years ago Placing GoodRx Under Review GoodRx is a consumer-focused digital healthcare platform that aims to lower the cost of healthcare in the United States. It has over 6 million active monthly users. The company’s primary focus is the U.S. prescription drug market, where GoodRx has developed a price comparison tool that it aggregates from over 200 billion daily pricing data points, directing consumers toward coupons negotiated between a pharmacy and intermediaries (pharmacy benefit managers ). GoodRx generates revenue by taking a small share of the fees paid by pharmacies to PBMs in exchange for routing consumers to these discount programs, and separately through a subscription-based model (GoodRx Gold), which offers discounted drugs to customers paying a monthly membership fee. Rating Price Target Morningstar• 2 years ago GoodRx Shares Tumble After Full-Year Guidance Pulled on News of Grocer-PBMs Dispute GoodRx is a consumer-focused digital healthcare platform that aims to lower the cost of healthcare in the United States. It has over 6 million active monthly users. The company’s primary focus is the U.S. prescription drug market, where GoodRx has developed a price comparison tool that it aggregates from over 200 billion daily pricing data points, directing consumers toward coupons negotiated between a pharmacy and intermediaries (pharmacy benefit managers ). GoodRx generates revenue by taking a small share of the fees paid by pharmacies to PBMs in exchange for routing consumers to these discount programs, and separately through a subscription-based model (GoodRx Gold), which offers discounted drugs to customers paying a monthly membership fee. Rating Price Target Morningstar• 2 years ago GoodRx Shares Tumble After Full-Year Guidance Pulled on News of Grocer-PBMs Dispute GoodRx is a consumer-focused digital healthcare platform that aims to lower the cost of healthcare in the United States. It has over 6 million active monthly users. The company’s primary focus is the U.S. prescription drug market, where GoodRx has developed a price comparison tool that it aggregates from over 200 billion daily pricing data points, directing consumers toward coupons negotiated between a pharmacy and intermediaries (pharmacy benefit managers ). GoodRx generates revenue by taking a small share of the fees paid by pharmacies to PBMs in exchange for routing consumers to these discount programs, and separately through a subscription-based model (GoodRx Gold), which offers discounted drugs to customers paying a monthly membership fee. Rating Price Target Morningstar• 2 years ago View Source3: GoodRx operates a price comparison platform for prescription drugs which, in many cases, offers consumers access to lower prices (through discount codes and coupons) for their medications. GoodRx generates most of its revenue from contracts with pharmacy benefit managers (“PBMs”) who agree to pay GoodRx a commission on prescription drug purchases made by consumers who use GoodRx’s discount codes and coupons at participating pharmacies. GoodRx also generates a portion of its revenue from subscription plans like the “Kroger Rx Savings Club,” which provides “access [to] lower prescription prices at” pharmacies operated by The Kroger Co. (“Kroger”). View Source4: GoodRx Holdings, Inc., together with its subsidiaries, offers information and tools that enable consumers to compare prices and save on their prescription drug purchases in the United States. The company operates a price comparison platform that provides consumers with curated, geographically relevant prescription pricing, and access to negotiated prices. It also offers other healthcare products and services, including subscriptions, and pharma manufacturer solutions, as well as telehealth services through the GoodRx Care platform. It serves pharmacy benefit managers who manage formularies and prescription transactions, including establishing pricing between consumers and pharmacies. The company was founded in 2011 and is headquartered in Santa Monica, California. View Source

UNKNOWN

The provided facts do not specify whether the founders of GoodRx Holdings Inc. are still leading the company or are heavily involved in its operations.

MEDIUM RISK

GoodRx Holdings Inc. faces a medium risk financial situation. While the company has a strong market presence and generates revenue through various channels, including PBM contracts and subscription plans 5 6, it has experienced significant disruptions. The over-dependence on Kroger, which accounted for nearly 25% of its prescription transactions revenue, led to a substantial revenue impact when Kroger ceased accepting GoodRx discounts 7 8. This disruption resulted in a notable decline in stock price and revenue guidance 9 10. Additionally, the company is involved in a class action lawsuit alleging securities fraud, which could pose further financial risks 11 12 13. Despite these challenges, GoodRx's strategic positioning and potential growth from initiatives like Integrated Savings Programs (ISPs) and partnerships with pharmaceutical companies provide a balanced outlook 14 15 16.

5: Dropping Coverage of GoodRx GoodRx is a consumer-focused digital healthcare platform that aims to lower the cost of healthcare in the United States. It has over 6 million active monthly users. The company’s primary focus is the U.S. prescription drug market, where GoodRx has developed a price comparison tool that it aggregates from over 200 billion daily pricing data points, directing consumers toward coupons negotiated between a pharmacy and intermediaries (pharmacy benefit managers ). GoodRx generates revenue by taking a small share of the fees paid by pharmacies to PBMs in exchange for routing consumers to these discount programs, and separately through a subscription-based model (GoodRx Gold), which offers discounted drugs to customers paying a monthly membership fee. Morningstar• 2 years ago Placing GoodRx Under Review GoodRx is a consumer-focused digital healthcare platform that aims to lower the cost of healthcare in the United States. It has over 6 million active monthly users. The company’s primary focus is the U.S. prescription drug market, where GoodRx has developed a price comparison tool that it aggregates from over 200 billion daily pricing data points, directing consumers toward coupons negotiated between a pharmacy and intermediaries (pharmacy benefit managers ). GoodRx generates revenue by taking a small share of the fees paid by pharmacies to PBMs in exchange for routing consumers to these discount programs, and separately through a subscription-based model (GoodRx Gold), which offers discounted drugs to customers paying a monthly membership fee. Rating Price Target Morningstar• 2 years ago GoodRx Shares Tumble After Full-Year Guidance Pulled on News of Grocer-PBMs Dispute GoodRx is a consumer-focused digital healthcare platform that aims to lower the cost of healthcare in the United States. It has over 6 million active monthly users. The company’s primary focus is the U.S. prescription drug market, where GoodRx has developed a price comparison tool that it aggregates from over 200 billion daily pricing data points, directing consumers toward coupons negotiated between a pharmacy and intermediaries (pharmacy benefit managers ). GoodRx generates revenue by taking a small share of the fees paid by pharmacies to PBMs in exchange for routing consumers to these discount programs, and separately through a subscription-based model (GoodRx Gold), which offers discounted drugs to customers paying a monthly membership fee. Rating Price Target Morningstar• 2 years ago GoodRx Shares Tumble After Full-Year Guidance Pulled on News of Grocer-PBMs Dispute GoodRx is a consumer-focused digital healthcare platform that aims to lower the cost of healthcare in the United States. It has over 6 million active monthly users. The company’s primary focus is the U.S. prescription drug market, where GoodRx has developed a price comparison tool that it aggregates from over 200 billion daily pricing data points, directing consumers toward coupons negotiated between a pharmacy and intermediaries (pharmacy benefit managers ). GoodRx generates revenue by taking a small share of the fees paid by pharmacies to PBMs in exchange for routing consumers to these discount programs, and separately through a subscription-based model (GoodRx Gold), which offers discounted drugs to customers paying a monthly membership fee. Rating Price Target Morningstar• 2 years ago View Source6: GoodRx operates a price comparison platform for prescription drugs which, in many cases, offers consumers access to lower prices (through discount codes and coupons) for their medications. GoodRx generates most of its revenue from contracts with pharmacy benefit managers (“PBMs”) who agree to pay GoodRx a commission on prescription drug purchases made by consumers who use GoodRx’s discount codes and coupons at participating pharmacies. GoodRx also generates a portion of its revenue from subscription plans like the “Kroger Rx Savings Club,” which provides “access [to] lower prescription prices at” pharmacies operated by The Kroger Co. (“Kroger”). View Source7: Investors began to learn the truth about the risks of GoodRx’s over-dependence on Kroger (including the risk that, notwithstanding the Kroger Rx Savings Club, Kroger could unilaterally refuse to accept GoodRx’s discounts) on May 9, 2022, when GoodRx revealed that, late in the first quarter of 2022, “a grocery chain had taken actions that impacted acceptance of discounts from most PBMs for a subset of drugs” and that this “impacted the acceptance of many PBM discounts for certain drugs at this grocer’s stores.” GoodRx further acknowledged that this disruption “could have an estimated revenue impact of roughly $30 million” in the second quarter of 2022—resulting in the Company announcing disappointing second quarter 2022 revenue guidance of only about $190 million. On this news, the price of GoodRx common stock plummeted $2.78 per share, or more than 25%, from a close of $10.75 per share on May 9, 2022, to close at $7.97 per share on May 10, 2022. View Source8: On November 8, 2022, Defendants provided further information on the severity of the revenue impact from the Kroger disruption—with the Company estimating that the “impact of the grocer issue on third quarter [prescription transactions revenue] was approximately $40 million” and that the Company expected “a combined $45 million to $50 million estimated impact to prescription transactions revenue” for the fourth quarter of 2022. Defendants further acknowledged that the Company was seeking to enter into contractual relationships with pharmacies to prevent similar disruptions from occurring in the future. On this news, the price of GoodRx common stock declined an additional $1.18 per share, or more than 22%, from a close of $5.24 per share on November 8, 2022, to close at $4.06 per share on November 9, 2022. View Source9: Investors began to learn the truth about the risks of GoodRx’s over-dependence on Kroger (including the risk that, notwithstanding the Kroger Rx Savings Club, Kroger could unilaterally refuse to accept GoodRx’s discounts) on May 9, 2022, when GoodRx revealed that, late in the first quarter of 2022, “a grocery chain had taken actions that impacted acceptance of discounts from most PBMs for a subset of drugs” and that this “impacted the acceptance of many PBM discounts for certain drugs at this grocer’s stores.” GoodRx further acknowledged that this disruption “could have an estimated revenue impact of roughly $30 million” in the second quarter of 2022—resulting in the Company announcing disappointing second quarter 2022 revenue guidance of only about $190 million. On this news, the price of GoodRx common stock plummeted $2.78 per share, or more than 25%, from a close of $10.75 per share on May 9, 2022, to close at $7.97 per share on May 10, 2022. View Source10: On November 8, 2022, Defendants provided further information on the severity of the revenue impact from the Kroger disruption—with the Company estimating that the “impact of the grocer issue on third quarter [prescription transactions revenue] was approximately $40 million” and that the Company expected “a combined $45 million to $50 million estimated impact to prescription transactions revenue” for the fourth quarter of 2022. Defendants further acknowledged that the Company was seeking to enter into contractual relationships with pharmacies to prevent similar disruptions from occurring in the future. On this news, the price of GoodRx common stock declined an additional $1.18 per share, or more than 22%, from a close of $5.24 per share on November 8, 2022, to close at $4.06 per share on November 9, 2022. View Source11: A class action lawsuit has been filed on behalf of those who purchased or acquired GoodRx Holdings, Inc. (“GoodRx”) (NASDAQ: GDRX) common stock between September 23, 2020 and November 8, 2022, both dates inclusive (the “Class Period”). View Source12: GoodRx Holdings, Inc. (NASDAQ: GDRX) Securities Fraud Class Action View Source13: CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of GoodRx investors who were adversely affected by alleged securities fraud between September 23, 2020 and November 8, 2022. Follow the link below to get more information and be contacted by a member of our team: View Source14: Stan Berenshteyn has given his Buy rating due to a combination of factors surrounding the current market dynamics and the strategic positioning of GoodRx Holdings. He believes that the scrutiny of Pharmacy Benefit Managers (PBMs) by the Federal Trade Commission (FTC) could act as a catalyst for the company, as it may expedite the implementation of Integrated Savings Programs (ISPs). These ISPs could directly address the FTC’s concerns regarding drug accessibility and affordability, potentially leading to an increase in GoodRx’s revenue estimates for 2024 and 2025. The FTC’s focus on PBMs is expected to create long-term risks, but GoodRx’s alignment with PBMs through ISPs is seen as a positive development that could strengthen its market position. Moreover, Berenshteyn anticipates that GoodRx is set up for a solid financial performance, referred to as a “beat & raise” scenario, in the year 2024. This optimism is based on the company’s revenue guidance, which suggests that GoodRx could meet or exceed its Marketplace Revenue targets without requiring additional growth in Prescription Transaction Revenue from its first-quarter run-rate. The analyst expects that the continued sequential growth, coupled with the potential upside from the ISPs, presents a favorable situation for investors. Consequently, Berenshteyn recommends buying GoodRx Holdings’ stock, especially during the current price dip, as a strategic investment decision. View Source15: Boehringer Ingelheim and GoodRx announce exclusive patient affordability initiative for Adalimumab-adbm injection, Boehringer's biosimilar to Humira® View Source16: GoodRx partners with Boehringer Ingelheim to discount Humira biosimilar View Source

YES

GoodRx Holdings Inc. is launching new product offerings, such as the "Prescription Cost Tracker" to spotlight key factors driving out-of-pocket medication costs in the U.S. 17.

17: GoodRx Launches New "Prescription Cost Tracker" to Spotlight Key Factors Driving Out-of-Pocket Medication Costs in the U.S. View Source

GoodRx Holdings Inc. has outlined a strategic expansion plan for 2024 through 2026 that focuses on leveraging regulatory scrutiny and enhancing its market position. The company aims to capitalize on the Federal Trade Commission's (FTC) scrutiny of Pharmacy Benefit Managers (PBMs) by implementing Integrated Savings Programs (ISPs) that could address concerns about drug accessibility and affordability, potentially boosting revenue estimates for 2024 and 2025 18. Additionally, GoodRx is expanding its partnerships, such as the collaboration with Boehringer Ingelheim to offer a low-cost biosimilar to Humira, which aims to increase access to affordable medication 19 20. These initiatives, coupled with the company's strong market presence and diversified revenue streams, position GoodRx for potential growth and improved financial performance in the coming years 21 22.

18: Stan Berenshteyn has given his Buy rating due to a combination of factors surrounding the current market dynamics and the strategic positioning of GoodRx Holdings. He believes that the scrutiny of Pharmacy Benefit Managers (PBMs) by the Federal Trade Commission (FTC) could act as a catalyst for the company, as it may expedite the implementation of Integrated Savings Programs (ISPs). These ISPs could directly address the FTC’s concerns regarding drug accessibility and affordability, potentially leading to an increase in GoodRx’s revenue estimates for 2024 and 2025. The FTC’s focus on PBMs is expected to create long-term risks, but GoodRx’s alignment with PBMs through ISPs is seen as a positive development that could strengthen its market position. Moreover, Berenshteyn anticipates that GoodRx is set up for a solid financial performance, referred to as a “beat & raise” scenario, in the year 2024. This optimism is based on the company’s revenue guidance, which suggests that GoodRx could meet or exceed its Marketplace Revenue targets without requiring additional growth in Prescription Transaction Revenue from its first-quarter run-rate. The analyst expects that the continued sequential growth, coupled with the potential upside from the ISPs, presents a favorable situation for investors. Consequently, Berenshteyn recommends buying GoodRx Holdings’ stock, especially during the current price dip, as a strategic investment decision. View Source19: Allen Lutz has given his Sell rating due to a combination of factors that raise concerns about GoodRx Holdings’ future performance. The partnership with Boehringer Ingelheim to offer a low-cost biosimilar to Humira exclusively through GoodRx is seen as a positive step in expanding access to affordable medication. However, there are critical uncertainties surrounding the affordability of the biosimilar for patients at the pharmacy counter, the competitive pricing under insurance plans, and the level of consumer awareness about the partnership. The lack of clarity on whether the doses provided are interchangeable also adds to the uncertainty. These concerns are compounded by broader issues within the generic reimbursement market, which is central to GoodRx’s business model. The market’s evolution could impact GoodRx’s profitability and market position. Lutz remains cautious about these dynamics, and as a result, maintains an Underperform rating with a price objective that is significantly lower than the current market price, suggesting a lack of confidence in the stock’s ability to maintain or grow its value in the near term. View Source20: GoodRx partners with Boehringer Ingelheim to discount Humira biosimilar View Source21: Stan Berenshteyn has given his Buy rating due to a combination of factors surrounding the current market dynamics and the strategic positioning of GoodRx Holdings. He believes that the scrutiny of Pharmacy Benefit Managers (PBMs) by the Federal Trade Commission (FTC) could act as a catalyst for the company, as it may expedite the implementation of Integrated Savings Programs (ISPs). These ISPs could directly address the FTC’s concerns regarding drug accessibility and affordability, potentially leading to an increase in GoodRx’s revenue estimates for 2024 and 2025. The FTC’s focus on PBMs is expected to create long-term risks, but GoodRx’s alignment with PBMs through ISPs is seen as a positive development that could strengthen its market position. Moreover, Berenshteyn anticipates that GoodRx is set up for a solid financial performance, referred to as a “beat & raise” scenario, in the year 2024. This optimism is based on the company’s revenue guidance, which suggests that GoodRx could meet or exceed its Marketplace Revenue targets without requiring additional growth in Prescription Transaction Revenue from its first-quarter run-rate. The analyst expects that the continued sequential growth, coupled with the potential upside from the ISPs, presents a favorable situation for investors. Consequently, Berenshteyn recommends buying GoodRx Holdings’ stock, especially during the current price dip, as a strategic investment decision. View Source22: GoodRx Holdings, Inc., together with its subsidiaries, offers information and tools that enable consumers to compare prices and save on their prescription drug purchases in the United States. The company operates a price comparison platform that provides consumers with curated, geographically relevant prescription pricing, and access to negotiated prices. It also offers other healthcare products and services, including subscriptions, and pharma manufacturer solutions, as well as telehealth services through the GoodRx Care platform. It serves pharmacy benefit managers who manage formularies and prescription transactions, including establishing pricing between consumers and pharmacies. The company was founded in 2011 and is headquartered in Santa Monica, California. View Source

Sources

1: Dropping Coverage of GoodRx GoodRx is a consumer-focused digital healthcare platform that aims to lower the cost of healthcare in the United States. It has over 6 million active monthly users. The company’s primary focus is the U.S. prescription drug market, where GoodRx has developed a price comparison tool that it aggregates from over 200 billion daily pricing data points, directing consumers toward coupons negotiated between a pharmacy and intermediaries (pharmacy benefit managers ). GoodRx generates revenue by taking a small share of the fees paid by pharmacies to PBMs in exchange for routing consumers to these discount programs, and separately through a subscription-based model (GoodRx Gold), which offers discounted drugs to customers paying a monthly membership fee. Morningstar• 2 years ago Placing GoodRx Under Review GoodRx is a consumer-focused digital healthcare platform that aims to lower the cost of healthcare in the United States. It has over 6 million active monthly users. The company’s primary focus is the U.S. prescription drug market, where GoodRx has developed a price comparison tool that it aggregates from over 200 billion daily pricing data points, directing consumers toward coupons negotiated between a pharmacy and intermediaries (pharmacy benefit managers ). GoodRx generates revenue by taking a small share of the fees paid by pharmacies to PBMs in exchange for routing consumers to these discount programs, and separately through a subscription-based model (GoodRx Gold), which offers discounted drugs to customers paying a monthly membership fee. Rating Price Target Morningstar• 2 years ago GoodRx Shares Tumble After Full-Year Guidance Pulled on News of Grocer-PBMs Dispute GoodRx is a consumer-focused digital healthcare platform that aims to lower the cost of healthcare in the United States. It has over 6 million active monthly users. The company’s primary focus is the U.S. prescription drug market, where GoodRx has developed a price comparison tool that it aggregates from over 200 billion daily pricing data points, directing consumers toward coupons negotiated between a pharmacy and intermediaries (pharmacy benefit managers ). GoodRx generates revenue by taking a small share of the fees paid by pharmacies to PBMs in exchange for routing consumers to these discount programs, and separately through a subscription-based model (GoodRx Gold), which offers discounted drugs to customers paying a monthly membership fee. Rating Price Target Morningstar• 2 years ago GoodRx Shares Tumble After Full-Year Guidance Pulled on News of Grocer-PBMs Dispute GoodRx is a consumer-focused digital healthcare platform that aims to lower the cost of healthcare in the United States. It has over 6 million active monthly users. The company’s primary focus is the U.S. prescription drug market, where GoodRx has developed a price comparison tool that it aggregates from over 200 billion daily pricing data points, directing consumers toward coupons negotiated between a pharmacy and intermediaries (pharmacy benefit managers ). GoodRx generates revenue by taking a small share of the fees paid by pharmacies to PBMs in exchange for routing consumers to these discount programs, and separately through a subscription-based model (GoodRx Gold), which offers discounted drugs to customers paying a monthly membership fee. Rating Price Target Morningstar• 2 years ago View Source2: Dropping Coverage of GoodRx GoodRx is a consumer-focused digital healthcare platform that aims to lower the cost of healthcare in the United States. It has over 6 million active monthly users. The company’s primary focus is the U.S. prescription drug market, where GoodRx has developed a price comparison tool that it aggregates from over 200 billion daily pricing data points, directing consumers toward coupons negotiated between a pharmacy and intermediaries (pharmacy benefit managers ). GoodRx generates revenue by taking a small share of the fees paid by pharmacies to PBMs in exchange for routing consumers to these discount programs, and separately through a subscription-based model (GoodRx Gold), which offers discounted drugs to customers paying a monthly membership fee. Morningstar• 2 years ago Placing GoodRx Under Review GoodRx is a consumer-focused digital healthcare platform that aims to lower the cost of healthcare in the United States. It has over 6 million active monthly users. The company’s primary focus is the U.S. prescription drug market, where GoodRx has developed a price comparison tool that it aggregates from over 200 billion daily pricing data points, directing consumers toward coupons negotiated between a pharmacy and intermediaries (pharmacy benefit managers ). GoodRx generates revenue by taking a small share of the fees paid by pharmacies to PBMs in exchange for routing consumers to these discount programs, and separately through a subscription-based model (GoodRx Gold), which offers discounted drugs to customers paying a monthly membership fee. Rating Price Target Morningstar• 2 years ago GoodRx Shares Tumble After Full-Year Guidance Pulled on News of Grocer-PBMs Dispute GoodRx is a consumer-focused digital healthcare platform that aims to lower the cost of healthcare in the United States. It has over 6 million active monthly users. The company’s primary focus is the U.S. prescription drug market, where GoodRx has developed a price comparison tool that it aggregates from over 200 billion daily pricing data points, directing consumers toward coupons negotiated between a pharmacy and intermediaries (pharmacy benefit managers ). GoodRx generates revenue by taking a small share of the fees paid by pharmacies to PBMs in exchange for routing consumers to these discount programs, and separately through a subscription-based model (GoodRx Gold), which offers discounted drugs to customers paying a monthly membership fee. Rating Price Target Morningstar• 2 years ago GoodRx Shares Tumble After Full-Year Guidance Pulled on News of Grocer-PBMs Dispute GoodRx is a consumer-focused digital healthcare platform that aims to lower the cost of healthcare in the United States. It has over 6 million active monthly users. The company’s primary focus is the U.S. prescription drug market, where GoodRx has developed a price comparison tool that it aggregates from over 200 billion daily pricing data points, directing consumers toward coupons negotiated between a pharmacy and intermediaries (pharmacy benefit managers ). GoodRx generates revenue by taking a small share of the fees paid by pharmacies to PBMs in exchange for routing consumers to these discount programs, and separately through a subscription-based model (GoodRx Gold), which offers discounted drugs to customers paying a monthly membership fee. Rating Price Target Morningstar• 2 years ago View Source3: GoodRx operates a price comparison platform for prescription drugs which, in many cases, offers consumers access to lower prices (through discount codes and coupons) for their medications. GoodRx generates most of its revenue from contracts with pharmacy benefit managers (“PBMs”) who agree to pay GoodRx a commission on prescription drug purchases made by consumers who use GoodRx’s discount codes and coupons at participating pharmacies. GoodRx also generates a portion of its revenue from subscription plans like the “Kroger Rx Savings Club,” which provides “access [to] lower prescription prices at” pharmacies operated by The Kroger Co. (“Kroger”). View Source4: GoodRx Holdings, Inc., together with its subsidiaries, offers information and tools that enable consumers to compare prices and save on their prescription drug purchases in the United States. The company operates a price comparison platform that provides consumers with curated, geographically relevant prescription pricing, and access to negotiated prices. It also offers other healthcare products and services, including subscriptions, and pharma manufacturer solutions, as well as telehealth services through the GoodRx Care platform. It serves pharmacy benefit managers who manage formularies and prescription transactions, including establishing pricing between consumers and pharmacies. The company was founded in 2011 and is headquartered in Santa Monica, California. View Source5: Dropping Coverage of GoodRx GoodRx is a consumer-focused digital healthcare platform that aims to lower the cost of healthcare in the United States. It has over 6 million active monthly users. The company’s primary focus is the U.S. prescription drug market, where GoodRx has developed a price comparison tool that it aggregates from over 200 billion daily pricing data points, directing consumers toward coupons negotiated between a pharmacy and intermediaries (pharmacy benefit managers ). GoodRx generates revenue by taking a small share of the fees paid by pharmacies to PBMs in exchange for routing consumers to these discount programs, and separately through a subscription-based model (GoodRx Gold), which offers discounted drugs to customers paying a monthly membership fee. Morningstar• 2 years ago Placing GoodRx Under Review GoodRx is a consumer-focused digital healthcare platform that aims to lower the cost of healthcare in the United States. It has over 6 million active monthly users. The company’s primary focus is the U.S. prescription drug market, where GoodRx has developed a price comparison tool that it aggregates from over 200 billion daily pricing data points, directing consumers toward coupons negotiated between a pharmacy and intermediaries (pharmacy benefit managers ). GoodRx generates revenue by taking a small share of the fees paid by pharmacies to PBMs in exchange for routing consumers to these discount programs, and separately through a subscription-based model (GoodRx Gold), which offers discounted drugs to customers paying a monthly membership fee. Rating Price Target Morningstar• 2 years ago GoodRx Shares Tumble After Full-Year Guidance Pulled on News of Grocer-PBMs Dispute GoodRx is a consumer-focused digital healthcare platform that aims to lower the cost of healthcare in the United States. It has over 6 million active monthly users. The company’s primary focus is the U.S. prescription drug market, where GoodRx has developed a price comparison tool that it aggregates from over 200 billion daily pricing data points, directing consumers toward coupons negotiated between a pharmacy and intermediaries (pharmacy benefit managers ). GoodRx generates revenue by taking a small share of the fees paid by pharmacies to PBMs in exchange for routing consumers to these discount programs, and separately through a subscription-based model (GoodRx Gold), which offers discounted drugs to customers paying a monthly membership fee. Rating Price Target Morningstar• 2 years ago GoodRx Shares Tumble After Full-Year Guidance Pulled on News of Grocer-PBMs Dispute GoodRx is a consumer-focused digital healthcare platform that aims to lower the cost of healthcare in the United States. It has over 6 million active monthly users. The company’s primary focus is the U.S. prescription drug market, where GoodRx has developed a price comparison tool that it aggregates from over 200 billion daily pricing data points, directing consumers toward coupons negotiated between a pharmacy and intermediaries (pharmacy benefit managers ). GoodRx generates revenue by taking a small share of the fees paid by pharmacies to PBMs in exchange for routing consumers to these discount programs, and separately through a subscription-based model (GoodRx Gold), which offers discounted drugs to customers paying a monthly membership fee. Rating Price Target Morningstar• 2 years ago View Source6: GoodRx operates a price comparison platform for prescription drugs which, in many cases, offers consumers access to lower prices (through discount codes and coupons) for their medications. GoodRx generates most of its revenue from contracts with pharmacy benefit managers (“PBMs”) who agree to pay GoodRx a commission on prescription drug purchases made by consumers who use GoodRx’s discount codes and coupons at participating pharmacies. GoodRx also generates a portion of its revenue from subscription plans like the “Kroger Rx Savings Club,” which provides “access [to] lower prescription prices at” pharmacies operated by The Kroger Co. (“Kroger”). View Source7: Investors began to learn the truth about the risks of GoodRx’s over-dependence on Kroger (including the risk that, notwithstanding the Kroger Rx Savings Club, Kroger could unilaterally refuse to accept GoodRx’s discounts) on May 9, 2022, when GoodRx revealed that, late in the first quarter of 2022, “a grocery chain had taken actions that impacted acceptance of discounts from most PBMs for a subset of drugs” and that this “impacted the acceptance of many PBM discounts for certain drugs at this grocer’s stores.” GoodRx further acknowledged that this disruption “could have an estimated revenue impact of roughly $30 million” in the second quarter of 2022—resulting in the Company announcing disappointing second quarter 2022 revenue guidance of only about $190 million. On this news, the price of GoodRx common stock plummeted $2.78 per share, or more than 25%, from a close of $10.75 per share on May 9, 2022, to close at $7.97 per share on May 10, 2022. View Source8: On November 8, 2022, Defendants provided further information on the severity of the revenue impact from the Kroger disruption—with the Company estimating that the “impact of the grocer issue on third quarter [prescription transactions revenue] was approximately $40 million” and that the Company expected “a combined $45 million to $50 million estimated impact to prescription transactions revenue” for the fourth quarter of 2022. Defendants further acknowledged that the Company was seeking to enter into contractual relationships with pharmacies to prevent similar disruptions from occurring in the future. On this news, the price of GoodRx common stock declined an additional $1.18 per share, or more than 22%, from a close of $5.24 per share on November 8, 2022, to close at $4.06 per share on November 9, 2022. View Source9: Investors began to learn the truth about the risks of GoodRx’s over-dependence on Kroger (including the risk that, notwithstanding the Kroger Rx Savings Club, Kroger could unilaterally refuse to accept GoodRx’s discounts) on May 9, 2022, when GoodRx revealed that, late in the first quarter of 2022, “a grocery chain had taken actions that impacted acceptance of discounts from most PBMs for a subset of drugs” and that this “impacted the acceptance of many PBM discounts for certain drugs at this grocer’s stores.” GoodRx further acknowledged that this disruption “could have an estimated revenue impact of roughly $30 million” in the second quarter of 2022—resulting in the Company announcing disappointing second quarter 2022 revenue guidance of only about $190 million. On this news, the price of GoodRx common stock plummeted $2.78 per share, or more than 25%, from a close of $10.75 per share on May 9, 2022, to close at $7.97 per share on May 10, 2022. View Source10: On November 8, 2022, Defendants provided further information on the severity of the revenue impact from the Kroger disruption—with the Company estimating that the “impact of the grocer issue on third quarter [prescription transactions revenue] was approximately $40 million” and that the Company expected “a combined $45 million to $50 million estimated impact to prescription transactions revenue” for the fourth quarter of 2022. Defendants further acknowledged that the Company was seeking to enter into contractual relationships with pharmacies to prevent similar disruptions from occurring in the future. On this news, the price of GoodRx common stock declined an additional $1.18 per share, or more than 22%, from a close of $5.24 per share on November 8, 2022, to close at $4.06 per share on November 9, 2022. View Source11: A class action lawsuit has been filed on behalf of those who purchased or acquired GoodRx Holdings, Inc. (“GoodRx”) (NASDAQ: GDRX) common stock between September 23, 2020 and November 8, 2022, both dates inclusive (the “Class Period”). View Source12: GoodRx Holdings, Inc. (NASDAQ: GDRX) Securities Fraud Class Action View Source13: CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of GoodRx investors who were adversely affected by alleged securities fraud between September 23, 2020 and November 8, 2022. Follow the link below to get more information and be contacted by a member of our team: View Source14: Stan Berenshteyn has given his Buy rating due to a combination of factors surrounding the current market dynamics and the strategic positioning of GoodRx Holdings. He believes that the scrutiny of Pharmacy Benefit Managers (PBMs) by the Federal Trade Commission (FTC) could act as a catalyst for the company, as it may expedite the implementation of Integrated Savings Programs (ISPs). These ISPs could directly address the FTC’s concerns regarding drug accessibility and affordability, potentially leading to an increase in GoodRx’s revenue estimates for 2024 and 2025. The FTC’s focus on PBMs is expected to create long-term risks, but GoodRx’s alignment with PBMs through ISPs is seen as a positive development that could strengthen its market position. Moreover, Berenshteyn anticipates that GoodRx is set up for a solid financial performance, referred to as a “beat & raise” scenario, in the year 2024. This optimism is based on the company’s revenue guidance, which suggests that GoodRx could meet or exceed its Marketplace Revenue targets without requiring additional growth in Prescription Transaction Revenue from its first-quarter run-rate. The analyst expects that the continued sequential growth, coupled with the potential upside from the ISPs, presents a favorable situation for investors. Consequently, Berenshteyn recommends buying GoodRx Holdings’ stock, especially during the current price dip, as a strategic investment decision. View Source15: Boehringer Ingelheim and GoodRx announce exclusive patient affordability initiative for Adalimumab-adbm injection, Boehringer's biosimilar to Humira® View Source16: GoodRx partners with Boehringer Ingelheim to discount Humira biosimilar View Source17: GoodRx Launches New "Prescription Cost Tracker" to Spotlight Key Factors Driving Out-of-Pocket Medication Costs in the U.S. View Source18: Stan Berenshteyn has given his Buy rating due to a combination of factors surrounding the current market dynamics and the strategic positioning of GoodRx Holdings. He believes that the scrutiny of Pharmacy Benefit Managers (PBMs) by the Federal Trade Commission (FTC) could act as a catalyst for the company, as it may expedite the implementation of Integrated Savings Programs (ISPs). These ISPs could directly address the FTC’s concerns regarding drug accessibility and affordability, potentially leading to an increase in GoodRx’s revenue estimates for 2024 and 2025. The FTC’s focus on PBMs is expected to create long-term risks, but GoodRx’s alignment with PBMs through ISPs is seen as a positive development that could strengthen its market position. Moreover, Berenshteyn anticipates that GoodRx is set up for a solid financial performance, referred to as a “beat & raise” scenario, in the year 2024. This optimism is based on the company’s revenue guidance, which suggests that GoodRx could meet or exceed its Marketplace Revenue targets without requiring additional growth in Prescription Transaction Revenue from its first-quarter run-rate. The analyst expects that the continued sequential growth, coupled with the potential upside from the ISPs, presents a favorable situation for investors. Consequently, Berenshteyn recommends buying GoodRx Holdings’ stock, especially during the current price dip, as a strategic investment decision. View Source19: Allen Lutz has given his Sell rating due to a combination of factors that raise concerns about GoodRx Holdings’ future performance. The partnership with Boehringer Ingelheim to offer a low-cost biosimilar to Humira exclusively through GoodRx is seen as a positive step in expanding access to affordable medication. However, there are critical uncertainties surrounding the affordability of the biosimilar for patients at the pharmacy counter, the competitive pricing under insurance plans, and the level of consumer awareness about the partnership. The lack of clarity on whether the doses provided are interchangeable also adds to the uncertainty. These concerns are compounded by broader issues within the generic reimbursement market, which is central to GoodRx’s business model. The market’s evolution could impact GoodRx’s profitability and market position. Lutz remains cautious about these dynamics, and as a result, maintains an Underperform rating with a price objective that is significantly lower than the current market price, suggesting a lack of confidence in the stock’s ability to maintain or grow its value in the near term. View Source20: GoodRx partners with Boehringer Ingelheim to discount Humira biosimilar View Source21: Stan Berenshteyn has given his Buy rating due to a combination of factors surrounding the current market dynamics and the strategic positioning of GoodRx Holdings. He believes that the scrutiny of Pharmacy Benefit Managers (PBMs) by the Federal Trade Commission (FTC) could act as a catalyst for the company, as it may expedite the implementation of Integrated Savings Programs (ISPs). These ISPs could directly address the FTC’s concerns regarding drug accessibility and affordability, potentially leading to an increase in GoodRx’s revenue estimates for 2024 and 2025. The FTC’s focus on PBMs is expected to create long-term risks, but GoodRx’s alignment with PBMs through ISPs is seen as a positive development that could strengthen its market position. Moreover, Berenshteyn anticipates that GoodRx is set up for a solid financial performance, referred to as a “beat & raise” scenario, in the year 2024. This optimism is based on the company’s revenue guidance, which suggests that GoodRx could meet or exceed its Marketplace Revenue targets without requiring additional growth in Prescription Transaction Revenue from its first-quarter run-rate. The analyst expects that the continued sequential growth, coupled with the potential upside from the ISPs, presents a favorable situation for investors. Consequently, Berenshteyn recommends buying GoodRx Holdings’ stock, especially during the current price dip, as a strategic investment decision. View Source22: GoodRx Holdings, Inc., together with its subsidiaries, offers information and tools that enable consumers to compare prices and save on their prescription drug purchases in the United States. The company operates a price comparison platform that provides consumers with curated, geographically relevant prescription pricing, and access to negotiated prices. It also offers other healthcare products and services, including subscriptions, and pharma manufacturer solutions, as well as telehealth services through the GoodRx Care platform. It serves pharmacy benefit managers who manage formularies and prescription transactions, including establishing pricing between consumers and pharmacies. The company was founded in 2011 and is headquartered in Santa Monica, California. View Source